Presentations will highlight the broad potential treatment opportunities for its clinical-stage targeted therapeutics HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) with further demonstrations ...
SAN FRANCISCO and SINGAPORE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat ...
Hummingbird Bioscience Announces Poster Presentation on HMBD-802, Novel Dual-Payload Antibody-Drug Conjugate, at EORTC-NCI-AACR 2024 GlobeNewswire October 23, 2024 SAN FRANCISCO and SINGAPORE, Oct. 23 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results